551 related articles for article (PubMed ID: 28751558)
1. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
[TBL] [Abstract][Full Text] [Related]
2. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Thorp BC; Badoux X
Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
[TBL] [Abstract][Full Text] [Related]
3. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
Lentz R; Feinglass J; Ma S; Akhter N
Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
[TBL] [Abstract][Full Text] [Related]
6. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Coutre SE; Byrd JC; Hillmen P; Barrientos JC; Barr PM; Devereux S; Robak T; Kipps TJ; Schuh A; Moreno C; Furman RR; Burger JA; O'Dwyer M; Ghia P; Valentino R; Chang S; Dean JP; James DF; O'Brien SM
Blood Adv; 2019 Jun; 3(12):1799-1807. PubMed ID: 31196847
[TBL] [Abstract][Full Text] [Related]
8. Management of adverse effects/toxicity of ibrutinib.
Paydas S
Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
[TBL] [Abstract][Full Text] [Related]
9. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
Shanafelt TD; Parikh SA; Noseworthy PA; Goede V; Chaffee KG; Bahlo J; Call TG; Schwager SM; Ding W; Eichhorst B; Fischer K; Leis JF; Chanan-Khan AA; Hallek M; Slager SL; Kay NE
Leuk Lymphoma; 2017 Jul; 58(7):1630-1639. PubMed ID: 27885886
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib-Associated Atrial Fibrillation.
Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
[TBL] [Abstract][Full Text] [Related]
11. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
Chai KL; Rowan G; Seymour JF; Burbury K; Carney D; Tam CS
Leuk Lymphoma; 2017 Dec; 58(12):2811-2814. PubMed ID: 28504030
[TBL] [Abstract][Full Text] [Related]
12. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Tang CPS; McMullen J; Tam C
Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
[TBL] [Abstract][Full Text] [Related]
13. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
15. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
16. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
17. Risk of Major Bleeding with Ibrutinib.
Mock J; Kunk PR; Palkimas S; Sen JM; Devitt M; Horton B; Portell CA; Williams ME; Maitland H
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):755-761. PubMed ID: 30077698
[TBL] [Abstract][Full Text] [Related]
18. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
20. How I treat CLL patients with ibrutinib.
Brown JR
Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]